切换至 "中华医学电子期刊资源库"
高级检索
中华肥胖与代谢病电子杂志

中华肥胖与代谢病电子杂志 ›› 2020, Vol. 06 ›› Issue (04) : 227 -232. doi: 10.3877/cma.j.issn.2095-9605.2020.04.004

所属专题： 总编推荐； 文献；

论著

袖状胃切除术早期对肥胖症患者血清白脂素水平的影响
李影1, 付真真2, 周红文2, 梁辉3, 管蔚3,†()   
  1. 1. 225001　扬州，江苏省苏北人民医院内分泌代谢科；210029　南京，南京医科大学第一附属医院内分泌代谢科
    2. 210029　南京，南京医科大学第一附属医院内分泌代谢科
    3. 210029　南京，南京医科大学第一附属医院减重代谢外科
  • 收稿日期:2020-04-29 出版日期:2020-11-30
  • 通信作者: 管蔚
  • 基金资助:
    吴阶平基金会临床科研专项基金(编号：320.2710.1807)

Short-term effect of sleeve gastrectomy on serum asprosin level in obese patients.

Ying Li1, Zhenzhen Fu2, Hongwen Zhou2, Hui Liang3, Wei Guan3,†()   

  1. 1. Department of Endocrinology, Northern Jiangsu People’s Hospital, Yangzhou 225001; Department of Endocrinology and Metabolism, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
    2. Department of Endocrinology and Metabolism, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
    3. Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
  • Received:2020-04-29 Published:2020-11-30
  • Corresponding author: Wei Guan
  • About author:
    Corresponding author: Guan Wei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李影, 付真真, 周红文, 梁辉, 管蔚. 袖状胃切除术早期对肥胖症患者血清白脂素水平的影响[J]. 中华肥胖与代谢病电子杂志, 2020, 06(04): 227-232.

Ying Li, Zhenzhen Fu, Hongwen Zhou, Hui Liang, Wei Guan. Short-term effect of sleeve gastrectomy on serum asprosin level in obese patients.[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2020, 06(04): 227-232.

目的

初步探讨腹腔镜袖状胃切除术（LSG）后短期内肥胖症患者血清白脂素（asprosin）和代谢指标的变化，并分析asprosin与代谢指标改善的相关性。

方法

回顾性分析2017年11月至2018年10月在南京医科大学第一附属医院减重代谢外科接受LSG治疗的20例肥胖症患者的病例资料，所有患者的体质量指数（BMI）>35 kg/m2。收集术前和术后3个月患者临床资料和空腹血清标本，使用Inbody 770测定人体成分指标。采用全自动生化分析仪测定生化指标，计算稳态模型评估胰岛素抵抗指数（HOMA-IR）。采用酶联免疫吸附法检测血清asprosin水平。

结果

术后3个月，患者的体重从（105.37±17.79）kg下降到（90.13±16.13）kg，BMI从（37.85±4.64）kg/m2显著下降至（32.31±4.10）kg/m2（P<0.001）。同时，HOMA-IR水平从基线时的（8.44±5.24）显著降低至（3.17±1.44），（P<0.001），胰岛素抵抗得到明显改善。血清asprosin浓度从术前的347.33（267.25，451.18）pg/mL下降至254.95（233.94，311.88）pg/mL，差异有统计学意义（P<0.01）。相关性分析和多元回归分析发现，术前受试者空腹血清asprosin水平与HOMA-IR呈独立正相关（r=0.564，P=0.01）；术后3月，asprosin的减少量与HOMA-IR的改善水平也呈独立正相关（r=0.517，P=0.019），与体重、BMI、空腹血糖、血脂等代谢指标变化水平无相关性。

结论

肥胖患者空腹血清asprosin水平与胰岛素抵抗密切相关，LSG手术短期内引起血清asprosin水平显著下降，且asprosin水平的变化与胰岛素抵抗的减轻及早期代谢获益密切相关，asprosin可能在胰岛素抵抗、肥胖和糖尿病之间发挥重要作用。

关键词: 肥胖症, 白脂素, 胰岛素抵抗, 代谢手术, 袖状胃切除术
Objective

To investigate the short-term effect of laparoscopic sleeve gastrectomy (LSG) on serum asprosin level in obesity, and to analyze the correlation with clinical outcomes.

Methods

20 adults with obesity (BMI>35 kg/m2) receiving LSG at Department of Bariatric and Metabolic Surgery, The First Affiliated Hospital with Nanjing Medical University were included to this study between Nov 2017 and Oct 2018. Clinical measurements and laboratory determinations were performed before surgery and 3 months after surgery. The body composition indexes were measured by inbody770 and the biochemical indexes were measured by automatic biochemical analyzer. Homeostasis model assessment of insulin resistance index (HOMA-IR) was calculated. Fasting serum asprosin was analyzed by ELISA.

Results

3 months after LSG, mean total body weight decreased from (105.37±17.79) kg at baseline to (90.13±16.13) kg (P<0.001). The subjects showed a marked weight loss accompanied by significantly lower BMI values (pre, 37.85±4.64 kg/m2, vs. post, 32.31±4.10 kg/m2, P<0.001) after LSG. Meanwhile, insulin resistance improved remarkably after LSG as displayed by reductions in HOMA-IR levels (pre, 8.44±5.24 vs. post, 3.17±1.44, P<0.001). Serum fasting asprosin levels markedly reduced from 347.33 (267.25, 451.18) pg/mL to 254.95 (233.94, 311.88) pg/ml at 3 month after LSG (P<0.01). Multivariate analyses showed that the fasting serum asprosin was positively correlated with HOMA-IR (r=0.564, P=0.01) before LSG. Moreover, when assessing 3-months postoperative changes, a positive correlation was found between the variation of asprosin and the reduction of HOMA-IR (r=0.517, P=0.019). However, there was no association between asprosin and the changes of body weight, BMI, fasting glucose and blood lipids in our study.

Conclusions

Fasting serum asprosin in obesity was closely related to insulin resistance before surgery and reduced significantly in the short term after LSG. Moreover, the early change of asprosin was strongly associated with the improvement of insulin resistance. Asprosin may play an important role in insulin resistance, obesity and diabetes.

Key words: Obesity, Asprosin, Insulin resistance, Bariatric surgery, Sleeve gastrectomy
表1 LSG术前20例受试者的基本资料
指标 术前
年龄（岁） 28.55±6.69
性别（男：女） 5:15
体重（kg） 105.37±17.79
BMI（kg/m2） 37.85±4.64
高血压病（人/%） 7 (35%)
高脂血症（人/%） 8 (40%)
T2DM（人/%） 2 (10%)
IR（人/%） 17 (85%)
HbA1c（%） 5.92 ±1.06
表2 20例肥胖受试者LSG术后3月人体成分指标的变化
指标 体重（kg） BMI （kg/m2） BF（kg） PBF（%） VFA（cm2） 腰围（cm）
术前 105.37±17.79 37.85±4.64 47.82±11.23 44.89±5.68 212.56±41.47 116.78±12.24
3月 90.13±16.13 32.31±4.10 40.14±10.68 42.41±5.90 190.64±45.15 103.38±13.68
P值 <0.001a <0.001a <0.001a 0.014a <0.001a <0.001a
指标 体重（kg） 臀围（cm） WHR BMR（kcal） SBP（mmHg） DBP（mmHg）
术前 105.37±17.79 119.37±8.30 1.01±0.05 1568.00(1487.75, 1799.75) 137.35±13.12 85.20±11.43
3月 90.13±16.13 110.55±9.11 0.99±0.06 1397.50(1315.50, 1656.25) 122.50±11.44 77.90±8.84
P值 <0.001a <0.001a 0.001a <0.001b <0.001a 0.006a
图1 LSG术后3月肥胖患者血清asprosin水平变化（*表示差异有统计学意义，P<0.001）
表3 20例肥胖受试者LSG术后3月代谢指标的变化
指标 FPG(mmol/L) FINS(pmol/L) HbA1c(%) HOMA-IR TG(mmol/L) TC(mmol/L)
术前 5.54±0.81 239.30 (115.40, 291.00) 5.80 (5.23, 6.08) 8.44 ±5.24 1.60±0.83 5.02 ±0.99
3月 5.07±0.72 80.80(59.45, 129.10) 5.00(4.90, 5.35) 3.17±1.44 1.25±0.35 4.21±0.97
P值 0.01a <0.001b <0.001b <0.001a 0.075a <0.001a
指标 LDL-C(mmol/L) HDL-C(mmol/L) ALT(U/L) AST(U/L) GGT(U/L) asprosin(pg/ml)
术前 3.58 ±0.83 0.99 ±0.19 46.10 (19.45, 105.50) 39.82±25.92 29.75(20.53, 48.48) 347.33(267.25, 451.18)
3月 2.94±0.78 0.91±019 45.10(35.83, 67.00) 46.78±19.89 19.90(13.85, 27.43) 254.95(233.94, 311.88)
P值 0.001a 0.060a 0.247b 0.196a 0.009b <0.001b
图2 术前肥胖患者血清asprosin与HOMA-IR相关性分析
图3 LSG术后3月血清asprosin的改变量与糖脂代谢指标改变量的相关性分析
[1]
GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years[J]. N Engl J Med, 2017, 377(1): 13-27.
[2]
GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 386(10010): 2287-2323.
[3]
Chu Wan-Loy, Phang Siew-Moi. Marine Algae as a Potential Source for Anti-Obesity Agents[J]. Mar Drugs, 2016, 14(12): 222.
[4]
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes[J]. N Engl J Med, 2012, 366(17): 1577-1585.
[5]
Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA, 2012, 307(1): 56-65.
[6]
Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fasting-induced glucogenic protein hormone[J]. Cell, 2016, 165(3): 566-579.
[7]
Greenhill C. Liver: Asprosin - new hormone involved in hepatic glucose release[J]. Nat Rev Endocrinol, 2016, 12(6): 312.
[8]
Hans PK, Guan W, Lin S, et al. Long-term outcome of laparoscopic sleeve gastrectomy from a single center in mainland China[J]. Asian J Surg, 2018, 41(3): 285-290.
[9]
Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions [J]. Diabetes Care, 2003, 26(3): 575-581.
[10]
Michael P. Czech. Insulin action and resistance in obesity and type 2 diabetes[J]. Nat Med. 2017, 23(7): 804-814.
[11]
Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States[J]. Ann N Y Acad Sci, 2013, 1281(1): 64-91.
[12]
Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone[J]. Nat Med, 2017, 23(12): 1444-1453.
[13]
Kajimura S. Adipose tissue in 2016: advances in the understanding of adipose tissue biology[J]. Nat Rev Endocrinol, 2017, 13(2): 69-70.
[14]
Wang Y, Qu H, Xiong X, et al. Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and Insulin Secretion[J]. Mediators Inflamm, 2018, 2018: 9471583.
[15]
Zhang L, Chen C, Zhou N, et al. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride[J]. Clin Chim Acta, 2019, 489: 183-188.
[16]
Wang CY, Lin TA, Liu KH, et al. Serum asprosin levels and bariatric surgery outcomes in obese adults[J]. Int J Obes, 2019, 43(5): 1019-1025.
[17]
Alan M, Gurlek B, Yilmaz A, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome[J]. Gynecol Endocrinol, 2019, 35(3): 220-223.
[18]
Acara AC, Bolatkale M, Kızıloğlu İ, et al. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin[J]. Am J Emerg Med, 2018, 36(8): 1504-1505.
[19]
Zhang Q, Ramracheya R, Lahmann C, et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes[J]. Cell Metab, 2013, 18(6): 871-882.
[20]
Thorens B. Brain glucose sensing and neural regulation of insulin and glucagon secretion[J]. Diabetes Obes Metab, 2011, 13 (S1): 82-88.
[1] 陈嘉婷, 杜美君, 石冰, 黄汉尧. 母体系统性疾病对新生儿唇腭裂发生的影响[J]. 中华口腔医学研究杂志(电子版), 2024, 18(04): 262-268.
[2] 孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[3] 吉顺富, 汤晓燕, 徐进. 腹腔镜近端胃癌根治术中拓展胃后间隙在肥胖患者中的应用研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 393-396.
[4] 杨波, 胡旭, 何金艳, 谢铭. 腹腔镜袖状胃切除术管胃固定研究现状[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 452-455.
[5] 赵帅, 王伟, 李瑞奇, 周家杰, 王道荣. 3D腹腔镜下袖状胃切除术治疗肥胖合并2型糖尿病的临床疗效及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 146-149.
[6] 刘盾, 潘晟. 不同入路腹腔镜袖状胃切除术用于肥胖症合并2型糖尿病的效果[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 150-154.
[7] 颜帅, 胡旭, 苟晓梅, 谢铭. 腹腔镜胃袖状切除术后并发症处置策略[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 220-224.
[8] 孙琳, 韩萍萍, 张碧琳, 张军霞. 血清WISP1水平与2型糖尿病患者血尿酸升高的相关性[J]. 中华临床医师杂志(电子版), 2024, 18(02): 178-182.
[9] 中国医师协会外科医师分会肥胖和代谢病外科专家工作组, 中国医师协会外科医师分会肥胖代谢外科综合管理专家工作组, 中国肥胖代谢外科研究协作组. 中国肥胖代谢外科数据库：2023年度报告[J]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 73-83.
[10] 孙海涛, 闫文貌, 郝少龙, 孙武青, 韩威, 白日星. 保留His角完整性对腹腔镜袖状胃切除术后胃食管反流的影响[J]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 84-87.
[11] 颜宥彤, 赵锐, 万谦益, 张贵祥, 沈弘毅, 程中, 陈亿. GLP-1受体激动剂——司美格鲁肽的应用及安全性[J]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 88-93.
[12] 周彪, 李政奇, 孟化. 肥胖与内镜下减重治疗研究进展[J]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 100-107.
[13] 王婉杰, 宋文超, 王键, 倪良晨, 洪健, 朱孝成, 姚立彬. 肥胖与中枢神经系统调控的研究进展[J]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 108-112.
[14] 陆远欣, 龚莉琳, 曾梦华. 肥胖与非酒精性脂肪肝研究进展[J]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 113-119.
[15] 庄建彬, 杨明建. 肥胖与结直肠癌的研究进展[J]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 120-126.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号